Indian Panel Reviews Celsentri Clearances
An Indian expert panel has sought data on ViiV Healthcare's HIV entry inhibitor maraviroc (Selzentry/Celsentri) - among the drugs cleared, some years ago, with a trial waiver in the country and recommended for re-examination by a Parliamentary committee.
You may also be interested in...
In what's perhaps one of the most damning reports on industry and the regulatory mechanism in India in recent times, a parliamentary standing committee on health and family welfare has charged that more than 30 new drugs were approved in the country without undergoing clinical trials.
ViiV Healthcare, the new holder of rights to Celsentri (maraviroc), is in advanced discussions to potentially license out the HIV therapy in India, a move that could perhaps work in its favour against any potential compulsory licensing challenge.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.